In the landscape of modern medicine, few breakthroughs have transformed patient outcomes as radically as immunotherapy. As the scientific community inches closer to turning cancer into a manageable—or even curable—disease, the Cancer Research Institute (CRI) remains at the epicenter of this revolution. However, the path to discovery is long, arduous, and resource-intensive.
As August marks "Make-A-Will Month," the CRI is inviting its supporters to consider a profound, long-term commitment: including the organization in their wills or living trusts. This form of legacy giving is more than a financial transaction; it is an investment in the future of human health, ensuring that the next generation of researchers has the stability to pursue high-risk, high-reward breakthroughs.
Main Facts: The Power of Legacy Giving
At its core, a legacy gift is a deferred donation made through a will or estate plan. For the CRI, these bequests provide a sustainable foundation that allows the organization to fund research that might otherwise be overlooked by traditional, short-term grant cycles.
The decision to name the CRI as a beneficiary is often driven by a personal connection to the mission. Many supporters are former patients who have benefited from the very immunotherapy treatments the institute helped pioneer. Others are family members of those who sought treatment, motivated by a desire to ensure that future generations do not endure the same loss.
Crucially, the CRI has maintained a reputation for fiscal transparency, consistently earning four-star ratings from independent charity assessors. This ensures that donors can rest assured that their legacy will be managed with integrity, efficiency, and a singular focus on scientific advancement.
A Chronology of Progress: From Early Foundations to AI-Driven Discovery
The CRI’s history is a testament to the power of persistence. Founded on the belief that the immune system could be harnessed to fight cancer, the institute has spent decades funding research that was once dismissed as fringe science.
The Early Decades: Laying the Groundwork
In the mid-20th century, the concept of immunotherapy was largely theoretical. The CRI began by funding the "brightest minds" in immunology, fostering a community of scientists who shared data and challenged existing paradigms. Throughout the 1970s and 80s, these early investments laid the essential groundwork for understanding how T-cells could be retrained to recognize and eliminate tumor cells.
The Modern Era: Precision and Technology
As we move through the 2020s, the focus has shifted toward precision medicine. The integration of advanced computational models and artificial intelligence has accelerated the pace of discovery. Where researchers once spent years analyzing individual cell samples, they can now use AI-driven platforms to map the immune landscape of a tumor in a fraction of the time. This evolution is precisely why legacy giving is so vital: it provides the "long-tail" funding necessary for these complex, multi-year technological projects to reach clinical fruition.
Supporting Data: Why Your Contribution Matters
The impact of a legacy gift is not just a theoretical benefit; it is felt in the laboratory every day. To understand the magnitude of this impact, one must look at the breadth of research currently supported by the CRI:
- Neuro-Immunology: Researchers are exploring the link between sensory neurons and tumor progression in lung cancer. By understanding how the nervous system communicates with cancer cells, scientists are discovering new "off-switches" for tumor growth.
- Computational Immunology: Experts like Dr. Peng Jiang are leveraging machine learning to decode the language of T-cells. By analyzing how these cells infiltrate tumors, researchers can predict which patients will respond best to specific immunotherapies, moving the industry toward a truly personalized model of care.
- Clinical Investigation: The CRI’s CLIP (Cancer Research Institute Lloyd J. Old Memorial) Investigator program acts as a talent incubator, identifying early-career scientists who are poised to make the next major breakthrough.
Bequests of all sizes coalesce into a powerful financial engine. Whether a gift is large or modest, these funds are pooled to sustain the rigorous, years-long studies that define the CRI’s portfolio. Without this predictable revenue stream, many of these projects would be vulnerable to the volatility of federal funding cycles or shifting commercial priorities.
Official Responses: The Voice of the Beneficiaries and Stewards
The importance of these contributions is underscored by those who manage the funds and those who rely on them to carry out their work.
Stewardship and Accountability
Katherine Pooser, Director of Planned Giving at the CRI, emphasizes that trust is the primary currency of legacy giving. "When a person generously gives through a will or living trust, they can do so with confidence knowing CRI regularly receives recognition from third-party assessors for its good governance and fiscal responsibility," Pooser explains.
She notes that legacy gifts are the lifeblood of the organization’s research budget. "Supporters can also be confident that their gift makes a real difference. Bequests of every size come together to make up a substantial part of the funding that drives the next wave of immunotherapy developments."
The Investigator’s Perspective
For researchers on the front lines, the support is not just financial—it is professional and communal. Dr. Lloyd Bod, an assistant professor of medicine at Massachusetts General Hospital and a CRI Thompson Family Foundation CLIP Investigator, speaks to the unique role the institute plays in the scientific community.
"Being a CRI CLIP Investigator is an honor, and not only provides crucial funding, but also connects me with a network of researchers dedicated to making groundbreaking discoveries in immunotherapy," says Dr. Bod. "It is a commitment to pursuing innovative science that can lead to life-saving therapies for patients worldwide."
For Dr. Bod and his peers, the knowledge that their work is supported by donors who have "planned for the future" provides a unique sense of stability. It allows them to take the intellectual risks required for true innovation, rather than focusing solely on "safe" or incremental research.
Implications: Building a Future Immune to Cancer
The implications of legacy giving extend far beyond the immediate laboratory results. When a donor includes the CRI in their estate plans, they are essentially casting a vote for a future where cancer is no longer a terminal diagnosis.
Shaping the Future of Medicine
The shift toward immunotherapy is a fundamental change in the paradigm of oncology. Rather than attacking a cancer with radiation or systemic chemotherapy—which often harms healthy cells—immunotherapy empowers the patient’s own biology to do the work. The implication is a future with fewer side effects, higher remission rates, and a significantly better quality of life for survivors.
The Role of the Donor as a Stakeholder
Donors who opt for legacy giving become stakeholders in the scientific process. They are no longer just passive observers of medical news; they are active participants in the evolution of healthcare. This relationship is one of the most rewarding aspects of philanthropy, providing a way for individuals to leave an indelible mark on the world long after they are gone.
How to Get Involved: A Simple Path to Lasting Change
Making a legacy gift is often simpler than many donors imagine. It does not require extreme wealth, nor does it require immediate financial sacrifice.
- Consult Your Estate Planner: During "Make-A-Will Month," many legal professionals offer streamlined services for updating estate plans.
- Define Your Impact: You may choose to designate your gift to a specific area of interest, such as lung cancer research or AI-driven immunology, or you may provide an unrestricted gift that allows the CRI to direct funds to the most urgent needs.
- Contact the Office of Gift Planning: The CRI provides dedicated resources to help donors and their advisors understand the tax benefits and administrative steps required to establish a bequest.
As Katherine Pooser notes, the office is always available for a conversation. If you have questions about how to structure a gift, or if you simply wish to learn more about the research your legacy will support, you can contact the CRI office of gift planning at 212-792-5212.
In the final analysis, including the Cancer Research Institute in your will is a profound act of optimism. It is a belief that the scientists of tomorrow will stand on the shoulders of the donors of today. By choosing to support this mission, you are not just leaving an asset; you are leaving a legacy of hope, a commitment to rigorous science, and a tangible contribution to a world where cancer is a thing of the past.
